Integrated Filing — IndAS

General information about company

Scrip Code	539524
NSE Symbol	LALPATHLAB
MSEI Symbol	NOTLISTED
ISIN	INE600L01024
Name of company	Dr. Lal Path Labs Ltd.
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	31-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	24-10-2025
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.
Start date and time of board meeting	31-10-2025 10:30:00
End date and time of board meeting	31-10-2025 13:55:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results Ind-AS

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2025	01-04-2025
B	Date of end of reporting period	30-09-2025	30-09-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
1	Income
	Revenue from operations	73,060.00	1,40,040.00
	Other income	2,480.00	5,290.00
	Total income	75,540.00	1,45,330.00
2	Expenses
(a)	Cost of materials consumed	14,180.00	27,070.00
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00
(d)	Employee benefit expense	13,220.00	26,450.00
(e)	Finance costs	480.00	950.00
(f)	Depreciation, depletion and amortisation expense	4,050.00	7,510.00
(f)	Other Expenses
1	Fees to collection centers/channel partners	10,630.00	19,850.00
2	Other expenses	12,620.00	25,030.00
	Total other expenses	23,250.00	44,880.00
	Total expenses	55,180.00	1,06,860.00
3	Total profit before exceptional items and tax	20,360.00	38,470.00
4	Exceptional items	0.00	0.00
5	Total profit before tax	20,360.00	38,470.00
6	Tax expense
7	Current tax	4,730.00	9,230.00
8	Deferred tax	410.00	620.00
9	Total tax expenses	5,140.00	9,850.00
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	Net Profit Loss for the period from continuing operations	15,220.00	28,620.00
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	Net profit (loss) from discontinued operation after tax	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	Total profit (loss) for period	15,220.00	28,620.00
17	Other comprehensive income net of taxes	150.00	60.00
18	Total Comprehensive Income for the period	15,370.00	28,680.00
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	15,060.00	28,300.00
	Total profit or loss, attributable to non-controlling interests	160.00	320.00
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	15,210.00	28,360.00
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	160.00	320.00
21	Details of equity share capital
	Paid-up equity share capital	8,380.00	8,380.00
	Face value of equity share capital	10	10
27	Details of debt securities
22	Reserves excluding revaluation reserve
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	18.05	33.93
	Diluted earnings (loss) per share from continuing operations	18.01	33.87
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	18.05	33.93
	Diluted earnings (loss) per share from continuing and discontinued operations	18.01	33.87
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		Textual Information(1)

Disclosure of notes on financial results

Textual Information(1)	i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 October, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2025 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. During the six months ended 30 September 2025, the Parent Company has issued 183,775 equity shares of face value of INR 10 each , to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 (ESOP Plan, 2022). v. The Board of Directors of the Parent Company have approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025. The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025 The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. vi. The Hon’ble Allahabad Bench of the National Company Law Tribunal (‘Hon’ble Tribunal’ or ‘NCLT’) sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the ‘pooling of interests’ method in accordance with Ind AS 103 “Business Combinations” and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company. vii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited (SDIPL), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025. viii. The Board of Director's of Parent company at their meeting held on 31 October, 2025 approved issuance of bonus shares, in the proportion of 1:1 i.e 1 (one) bonus equity share of INR 10 each for every 1 (one) fully paid-up equity share , subject to Shareholders approvals. ix. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024. x. As at 30 September,2025, the Parent company has the following subsidiaries: Subsidiaries Paliwal Diagnostics Private Limited Dr. Lal PathLabs Nepal Private Limited Dr. Lal PathLabs Bangladesh Private Limited Dr. Lal Ventures Private Limited PathLabs Unifiers Private Limited Step-down subsidiaries Centrapath Labs Private Limited APRL PathLabs Private Limited Chanre Laboratory Private Limited JV/Associate Company- Nil xi. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. xii. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure-B for Consolidated Cash Flow Statement.

Textual Information(1)

i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 October, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2025 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. During the six months ended 30 September 2025, the Parent Company has issued 183,775 equity shares of face value of INR 10 each , to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 (ESOP Plan, 2022). v. The Board of Directors of the Parent Company have approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025. The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025 The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. vi. The Hon’ble Allahabad Bench of the National Company Law Tribunal (‘Hon’ble Tribunal’ or ‘NCLT’) sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the ‘pooling of interests’ method in accordance with Ind AS 103 “Business Combinations” and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company. vii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited (SDIPL), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025. viii. The Board of Director's of Parent company at their meeting held on 31 October, 2025 approved issuance of bonus shares, in the proportion of 1:1 i.e 1 (one) bonus equity share of INR 10 each for every 1 (one) fully paid-up equity share , subject to Shareholders approvals. ix. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024. x. As at 30 September,2025, the Parent company has the following subsidiaries: Subsidiaries Paliwal Diagnostics Private Limited Dr. Lal PathLabs Nepal Private Limited Dr. Lal PathLabs Bangladesh Private Limited Dr. Lal Ventures Private Limited PathLabs Unifiers Private Limited Step-down subsidiaries Centrapath Labs Private Limited APRL PathLabs Private Limited Chanre Laboratory Private Limited JV/Associate Company- Nil xi. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. xii. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure-B for Consolidated Cash Flow Statement.

Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	42,930.00
	Capital work-in-progress	1,660.00
	Investment property	3,320.00
	Goodwill	54,810.00
	Other intangible assets	22,090.00
	Intangible assets under development	100.00
	Biological assets other than bearer plants	0.00
	Investments accounted for using equity method	0.00
	Non-current financial assets
	Non-current investments	0.00
	Trade receivables, non-current	0.00
	Loans, non-current	0.00
	Other non-current financial assets	8,340.00
	Total non-current financial assets	8,340.00
	Deferred tax assets (net)	7,980.00
	Other non-current assets	2,730.00
	Total non-current assets	1,43,960.00
2	Current assets
	Inventories	5,020.00
	Current financial asset
	Current investments	48,550.00
	Trade receivables, current	10,110.00
	Cash and cash equivalents	11,610.00
	Bank balance other than cash and cash equivalents	70,010.00
	Loans, current	180.00
	Other current financial assets	3,800.00
	Total current financial assets	1,44,260.00
	Current tax assets (net)	0.00
	Other current assets	2,680.00
	Total current assets	1,51,960.00
3	Non-current assets classified as held for sale	0.00
4	Regulatory deferral account debit balances and related deferred tax Assets	0.00
	Total assets	2,95,920.00
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	8,380.00
	Other equity	2,30,400.00
	Total equity attributable to owners of parent	2,38,780.00
	Non controlling interest	3,430.00
	Total equity	2,42,210.00
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0.00
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.00
	Total Trade payable	0.00
	Other non-current financial liabilities	9,890.00
	Total non-current financial liabilities	9,890.00
	Provisions, non-current	210.00
	Deferred tax liabilities (net)	290.00
	Deferred government grants, Non-current	0.00
	Other non-current liabilities	0.00
	Total non-current liabilities	10,390.00
	Current liabilities
	Current financial liabilities
	Borrowings, current	0.00
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	2,120.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	17,010.00
	Total Trade payable	19,130.00
	Other current financial liabilities	12,150.00
	Total current financial liabilities	31,280.00
	Other current liabilities	5,030.00
	Provisions, current	4,110.00
	Current tax liabilities (Net)	2,900.00
	Deferred government grants, Current	0.00
	Total current liabilities	43,320.00
3	Liabilities directly associated with assets in disposal group classified as held for sale	0.00
4	Regulatory deferral account credit balances and related deferred tax liability	0.00
	Total liabilities	53,710.00
	Total equity and liabilites	2,95,920.00
	Disclosure of notes on assets and liabilities

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-07-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2025	01-04-2025
B	Date of end of reporting period	30-09-2025	30-09-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of the defined benefit obligations	180.00	60.00
	Total Amount of items that will not be reclassified to profit and loss	180.00	60.00
2	Income tax relating to items that will not be reclassified to profit or loss	50.00	20.00
3	Amount of items that will be reclassified to profit and loss
1	Exchange differences on translation of foreign operations	20.00	20.00
	Total Amount of items that will be reclassified to profit and loss	20.00	20.00
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	150.00	60.00

Cash flow statement, indirect

Amount in (Lakhs)

Particulars			Year ended (dd-mm-yyyy)
A	Date of start of reporting period		01-04-2025
B	Date of end of reporting period		30-09-2025
C	Whether results are audited or unaudited		Unaudited
D	Nature of report standalone or consolidated		Consolidated
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax		38,470.00
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs		950.00
	Adjustments for decrease (increase) in inventories		(1,410.00)
	Adjustments for decrease (increase) in trade receivables, current		(1,500.00)
	Adjustments for decrease (increase) in trade receivables, non-current		0.00
	Adjustments for decrease (increase) in other current assets		(460.00)
	Adjustments for decrease (increase) in other non-current assets		0.00
	Adjustments for other financial assets, non-current		0.00
	Adjustments for other financial assets, current		(260.00)
	Adjustments for other bank balances		0.00
	Adjustments for increase (decrease) in trade payables, current		1,190.00
	Adjustments for increase (decrease) in trade payables, non-current		0.00
	Adjustments for increase (decrease) in other current liabilities		(1,210.00)
	Adjustments for increase (decrease) in other non-current liabilities		0.00
	Adjustments for depreciation and amortisation expense		7,510.00
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss		0.00
	Adjustments for provisions, current		610.00
	Adjustments for provisions, non-current		0.00
	Adjustments for other financial liabilities, current		280.00
	Adjustments for other financial liabilities, non-current		0.00
	Adjustments for unrealised foreign exchange losses gains		0.00
	Adjustments for dividend income		0.00
	Adjustments for interest income		3,350.00
	Adjustments for share-based payments		1,380.00
	Adjustments for fair value losses (gains)		0.00
	Adjustments for undistributed profits of associates		0.00
	Other adjustments for which cash effects are investing or financing cash flow		0.00
	Other adjustments to reconcile profit (loss)		0.00
	Other adjustments for non-cash items		(1,490.00)
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships		0.00
	Total adjustments for reconcile profit (loss)		2,240.00
	Net cash flows from (used in) operations		40,710.00
	Dividends received		0.00
	Interest paid		0.00
	Interest received		0.00
	Income taxes paid (refund)		8,310.00
	Other inflows (outflows) of cash		0.00
	Net cash flows from (used in) operating activities		32,400.00
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses		0.00
	Cash flows used in obtaining control of subsidiaries or other businesses		0.00
	Other cash receipts from sales of equity or debt instruments of other entities		0.00
	Other cash payments to acquire equity or debt instruments of other entities		0.00
	Other cash receipts from sales of interests in joint ventures		0.00
	Other cash payments to acquire interests in joint ventures		0.00
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships		0.00
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships		0.00
	Proceeds from sales of property, plant and equipment		40.00
	Purchase of property, plant and equipment		13,440.00
	Proceeds from sales of investment property		0.00
	Purchase of investment property		0.00
	Proceeds from sales of intangible assets		0.00
	Purchase of intangible assets		480.00
	Proceeds from sales of intangible assets under development		0.00
	Purchase of intangible assets under development		0.00
	Proceeds from sales of goodwill		0.00
	Purchase of goodwill		0.00
	Proceeds from biological assets other than bearer plants		0.00
	Purchase of biological assets other than bearer plants		0.00
	Proceeds from government grants		0.00
	Proceeds from sales of other long-term assets		0.00
	Purchase of other long-term assets		0.00
	Cash advances and loans made to other parties		0.00
	Cash receipts from repayment of advances and loans made to other parties		0.00
	Cash payments for future contracts, forward contracts, option contracts and swap contracts		0.00
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts		0.00
	Dividends received		0.00
	Interest received		4,720.00
	Income taxes paid (refund)		0.00
	Other inflows (outflows) of cash		(29,640.00)
	Net cash flows from (used in) investing activities	(38,800.00)
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries		0.00
	Payments from changes in ownership interests in subsidiaries		0.00
	Proceeds from issuing shares		0.00
	Proceeds from issuing other equity instruments		0.00
	Payments to acquire or redeem entity's shares		0.00
	Payments of other equity instruments		0.00
	Proceeds from exercise of stock options		1,770.00
	Proceeds from issuing debentures notes bonds etc		0.00
	Proceeds from borrowings		0.00
	Repayments of borrowings		0.00
	Payments of lease liabilities		1,800.00
	Dividends paid		10,270.00
	Interest paid		10.00
	Income taxes paid (refund)		0.00
	Other inflows (outflows) of cash		(940.00)
	Net cash flows from (used in) financing activities		(11,250.00)
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes		(17,650.00)
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents		0.00
	Net increase (decrease) in cash and cash equivalents		(17,650.00)
	Cash and cash equivalents cash flow statement at beginning of period		29,260.00
	Cash and cash equivalents cash flow statement at end of period		11,610.00